

Timothy Bagguley

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5339174/publications.pdf>

Version: 2024-02-01

18
papers

252
citations

1306789

7
h-index

1058022

14
g-index

20
all docs

20
docs citations

20
times ranked

530
citing authors

#	ARTICLE	IF	CITATIONS
1	Cohort Profile Update: The Haematological Malignancy Research Network (HMRN) UK population-based cohorts. <i>International Journal of Epidemiology</i> , 2022, 51, e87-e94.	0.9	7
2	Toxic iron species in lower-risk myelodysplastic syndrome patients: course of disease and effects on outcome. <i>Leukemia</i> , 2021, 35, 1745-1750.	3.3	15
3	Health impact of monoclonal gammopathy of undetermined significance (MGUS) and monoclonal B-cell lymphocytosis (MBL): findings from a UK population-based cohort. <i>BMJ Open</i> , 2021, 11, e041296.	0.8	5
4	Frontline management of nodular lymphocyte predominant Hodgkin lymphoma – a retrospective UK multicentre study. <i>British Journal of Haematology</i> , 2019, 186, e214-e217.	1.2	9
5	Hodgkin lymphoma detection and survival: findings from the Haematological Malignancy Research Network. <i>BJCP Open</i> , 2019, 3, bjgpopen19X101668.	0.9	8
6	Health-related quality of life in lower-risk MDS patients compared with age- and sex-matched reference populations: a European LeukemiaNet study. <i>Leukemia</i> , 2018, 32, 1380-1392.	3.3	66
7	Labile plasma iron levels predict survival in patients with lower-risk myelodysplastic syndromes. <i>Haematologica</i> , 2018, 103, 69-79.	1.7	35
8	PCN351 - HEALTH-STATE UTILITY VALUES IN DIFFUSE LARGE B-CELL LYMPHOMA. <i>Value in Health</i> , 2018, 21, S74.	0.1	8
9	Cohort Profile: The Haematological Malignancy Research Network (HMRN): a UK population-based patient cohort. <i>International Journal of Epidemiology</i> , 2018, 47, 700-700g.	0.9	47
10	Elevated Labile Plasma Iron (LPI) Levels in Patients with Lower-Risk Myelodysplastic Syndromes (MDS) Are Associated with Decreased Quality of Life and Reduced Survival. <i>Blood</i> , 2018, 132, 4392-4392.	0.6	0
11	Matching Adjusted Indirect Comparison to Assess the Relative Efficacy of Idelalisib in Double-Refractory Follicular Lymphoma. <i>Blood</i> , 2018, 132, 5842-5842.	0.6	0
12	Multiple myeloma: routes to diagnosis, clinical characteristics and survival – findings from a UK population-based study. <i>British Journal of Haematology</i> , 2017, 177, 67-71.	1.2	39
13	Elevated Labile Plasma Iron Levels (LPI) and Increased Oxidative Stress Are Associated with Red Blood Cell Transfusions in Patients with Lower-Risk Myelodysplastic Syndromes (MDS) Subtitle: from the European Leukemianet MDS Registry. <i>Blood</i> , 2016, 128, 4327-4327.	0.6	1
14	Novel Targeted Therapies and Their Impact on Survival from Multiple Myeloma (MM) and Chronic Lymphocytic Leukaemia (CLL) in the Real World. <i>Blood</i> , 2016, 128, 3546-3546.	0.6	0
15	212 TRANSFUSIONS AND PRESENCE OF RINGSIDEROBLASTS INFLUENCE HEPCIDIN AND NTBI LEVELS IN PATIENTS WITH LOWER-RISK MYELODYSPLASTIC SYNDROMES (MDS) - A REPORT FROM THE EUROPEAN LEUKEMIANET MDS REGISTRY. <i>Leukemia Research</i> , 2015, 39, S106-S107.	0.4	0
16	Labile Plasma Iron (LPI) Is a Clinical Indicator of Overt Iron Overload in Patients with Lower-Risk Myelodysplastic Syndromes (MDS) from the European Leukemianet MDS Registry. <i>Blood</i> , 2015, 126, 2865-2865.	0.6	3
17	Hepcidin and GDF15 Levels during the First 2 Years Follow-up in Patients with Low and Int-1 Risk Myelodysplastic Syndromes (MDS) from the European Leukemianet MDS Registry. <i>Blood</i> , 2014, 124, 3267-3267.	0.6	0
18	Skeletal-Related Events In Myeloma: A Population-Based Study. <i>Blood</i> , 2013, 122, 3158-3158.	0.6	5